Enliven Therapeutics
Founded Year
2019Stage
Reverse Merger | IPOTotal Raised
$140MAbout Enliven Therapeutics
Enliven Therapeutics (NASDAQ: ELVN) is a biopharmaceutical company that focuses on discovering and developing small-molecule kinase inhibitors to address existing and emerging unmet needs in oncology. Its discovery process combines clinically validated biological targets and chemistry with the goal of designing therapies for cancer patients. The company was founded in 2019 and is based in Boulder, Colorado.
Missing: Enliven Therapeutics's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Enliven Therapeutics's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Enliven Therapeutics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Enliven Therapeutics is included in 1 Expert Collection, including Biopharma Tech.
Biopharma Tech
1,568 items
Enliven Therapeutics Patents
Enliven Therapeutics has filed 3 patents.
The 3 most popular patent topics include:
- Experimental cancer drugs
- Transcription factors
- Tyrosine kinase receptors
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
10/4/2021 | Application |
Application Date | 10/4/2021 |
|---|---|
Grant Date | |
Title | |
Related Topics | |
Status | Application |
Latest Enliven Therapeutics News
May 31, 2023
Time: 11:00 a.m. ET Format: Fireside Chat Time: 8:00 a.m. PT Both the presentation and fireside chat will be webcast live and can be accessed by visiting the investor relations section of the Company’s website at https://ir.enliventherapeutics.com/ . Each webcast will be archived for a period of 30 days following the conclusion of the live event. About Enliven Therapeutics Enliven Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer not only live longer, but better. Enliven aims to address existing and emerging unmet needs with a precision oncology approach that improves survival and enhances overall patient well-being. Enliven’s discovery process combines deep insights in clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies. Enliven is based in Boulder, Colorado. Contact:
Enliven Therapeutics Frequently Asked Questions (FAQ)
When was Enliven Therapeutics founded?
Enliven Therapeutics was founded in 2019.
Where is Enliven Therapeutics's headquarters?
Enliven Therapeutics's headquarters is located at 6200 Lookout Road, Boulder.
What is Enliven Therapeutics's latest funding round?
Enliven Therapeutics's latest funding round is Reverse Merger.
How much did Enliven Therapeutics raise?
Enliven Therapeutics raised a total of $140M.
Who are the investors of Enliven Therapeutics?
Investors of Enliven Therapeutics include Fidelity Investments, Frazier Healthcare Partners, Venrock Healthcare Capital Partners, Fairmount Funds Management, RA Capital Management and 12 more.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.